Legend Biotech Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LEGN Nasdaq 2836 legendbiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Legend Biotech Corporation

Legend Biotech (LEGN) Stock May Be Cheap After CEO Resignation - Jul 29th, 2026 4:08 am
Legend Biotech (LEGN) CEO Exit Tests Management Stability Around Its CAR-T Multiple Myeloma Strategy - Jul 29th, 2026 12:08 am
Legend Biotech (LEGN) Replaces CEO Ying Huang With Interim Chief Alan Bash - Jul 28th, 2026 10:27 pm
Leadership changes afoot at two CGT biotechs - Jul 28th, 2026 9:35 am
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results - Jul 28th, 2026 6:00 am
LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset - Jul 27th, 2026 12:35 pm
FDA scientists question Capricor data; Legend CEO steps down - Jul 27th, 2026 5:00 am
Legend Biotech Announces CEO Transition - Jul 27th, 2026 4:00 am
Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress - Jun 25th, 2026 6:40 am
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - Jun 24th, 2026 5:55 am
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - Jun 23rd, 2026 6:00 am
Legend Biotech (LEGN) Reports a Complete Response in Five of Six Patients at Its Highest Dose - Jun 22nd, 2026 8:14 am
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Interim US-Iran Deal Lifts Risk Sentiment - Jun 18th, 2026 6:57 am
Legend Biotech Corporation Announces Pricing of Public Offering - Jun 17th, 2026 7:21 pm
Legend Biotech Corporation Announces Proposed Public Offering - Jun 17th, 2026 2:29 pm
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma - Jun 15th, 2026 6:00 am
Legend Biotech (LEGN) Is Up 26.2% After Early In Vivo CAR-T Success in B-Cell Lymphoma - Jun 4th, 2026 7:12 am
Legend surges on early data for ‘in vivo’ lymphoma cell therapy - Jun 3rd, 2026 5:57 am
Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results - Jun 2nd, 2026 6:14 pm
Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next? - Jun 2nd, 2026 2:30 pm